SynthesisBMC complementary medicine and therapies2025
Systematic review and meta-analysis of bioactive hydrolysates derived from Saccharomyces cerevisiae on obesity management.
Synthesis in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a major public health challenge. Pharmacological treatments are effective but limited by high cost, side effects, and restricted accessibility, particularly in low- and middle-income countries. Nutraceuticals may provide complementary or alternative approaches. Saccharomyces cerevisiae-derived bioactive hydrolysates have shown promise in clinical trials, but their efficacy has not previously been synthesized in a meta-analysis.
methodsWe conducted a systematic review and meta-analysis following Cochrane and PRISMA 2020 guidelines (PROSPERO CRD420251024965). PubMed, SciELO, CENTRAL, ClinicalTrials.gov, Europe PMC, bioRxiv, medRxiv, and Preprints.org were searched (April-August 2025) for blinded, randomized, placebo-controlled trials in adults with overweight or obesity. Primary outcomes were changes in body weight, body mass index (BMI), fat mass, and waist circumference. Risk of bias was assessed using ROB-2, and certainty of evidence was graded with GRADE.
resultsSix randomized controlled trials (n = 262) were included. Compared with placebo, S. cerevisiae bioactive hydrolysates significantly reduced body weight (MD - 3.08 kg; 95% CI - 4.02 to - 2.13; p < 0.001; I² = 10%), BMI (MD - 0.87 kg/m²; 95% CI - 1.32 to - 0.41; p < 0.01; I² = 50%), and fat mass (MD - 1.93 kg; 95% CI - 3.36 to - 0.49; p < 0.05; I² = 64%). A non-significant trend was observed for waist circumference (MD - 2.47 cm; 95% CI - 5.09 to 0.16; p = 0.06; I² = 78%). All trials were assessed as low risk of bias, but heterogeneity downgraded the certainty of evidence to low.
conclusionsThis systematic review and meta-analysis demonstrate that S. cerevisiae-derived bioactive hydrolysates lead to statistically and clinically meaningful reductions in fat mass, BMI, waist circumference, and body weight. Their favorable safety and over-the-counter availability support their use as an accessible short-term option for obesity management. Further studies are warranted to evaluate long-term effects, durability of outcomes, and applicability in real-world settings.
trial registrationPROSPERO: CRD420251024965.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.